Literature DB >> 32926843

The molecular mechanism involved in cardioprotection by the dietary flavonoid fisetin as an agonist of PPAR-γ in a murine model of myocardial infarction.

Shanky Garg1, Sana Irfan Khan1, Rajiv Kumar Malhotra1, Manish Kumar Sharma2, Manoj Kumar3, Punit Kaur3, Tapas Chandra Nag2, Jagriti Bhatia1, Dharamvir Singh Arya4.   

Abstract

The methodology exploring the cardioprotective potential of the flavonoid Fisetin through its ability to modulate PPAR-γ was unraveled in the present study. Computational modelling through molecular docking based binding study of interactions between Fiestin and PPAR-γ revealed the potential role of Fisetin as an agonist of PPAR-γ. A murine model of cardiac ischemia-reperfusion injury was used to explore this further. Male Wistar Rats were randomly assigned to five groups. Fisetin (20 mg/kg; p. o) was administered for 28 days. Ischemia was induced for 45 min on the 29th day followed by 60 min of reperfusion. Fisetin pretreatment upregulated the expression of PPAR-γ in heart tissue significantly Cardioprotection was assessed by measurement of hemodynamic parameters, infarct size, ELISA for oxidative stress, immunohistochemistry and TUNEL assay for apoptosis, and western blot analysis for MAPK proteins and inflammation. PPAR-γ activation by fisetin led to significantly reduced infarct size, suppression of oxidative stress, reduction of cardiac injury markers, alleviation of inflammation, and inhibition of apoptosis The MAPK-based molecular mechanism showed a rise in a key prosurvival kinase, ERK1/ERK2 and suppression of JNK and p38 proteins. The aforementioned beneficial findings of fisetin were reversed on the administration of a specific antagonist of PPAR-γ. In conclusion, through our experiments, we have proved that fisetin protects the heart against ischemia-reperfusion injury and the evident cardioprotection is PPAR-γ dependant. In conclusion, our study has revealed a prime mechanism involved in the cardioprotective effects of fisetin. Hence, Fisetin may be evaluated in further clinical studies as a cardioprotective agent in patients undergoing reperfusion interventions.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardioprotective; Fisetin; Ischemia-reperfusion; MAPK; PPAR-γ

Year:  2020        PMID: 32926843     DOI: 10.1016/j.abb.2020.108572

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

1.  Gpx3 and Egr1 Are Involved in Regulating the Differentiation Fate of Cardiac Fibroblasts under Pressure Overload.

Authors:  Guoxing Li; Yuhong Qin; Zhe Cheng; Xiaocheng Cheng; Ruiyu Wang; Xuexiu Luo; Yipin Zhao; Dongying Zhang; Gang Li
Journal:  Oxid Med Cell Longev       Date:  2022-06-28       Impact factor: 7.310

Review 2.  Senescence in Vascular Smooth Muscle Cells and Atherosclerosis.

Authors:  Yiwen Zha; Wenwen Zhuang; Yongqi Yang; Yue Zhou; Hongliang Li; Jingyan Liang
Journal:  Front Cardiovasc Med       Date:  2022-06-01

3.  SLC6A8 Knockdown Suppresses the Invasion and Migration of Human Hepatocellular Carcinoma Huh-7 and Hep3B Cells.

Authors:  Lu Yuan; Xian Jian Wu; Wen Chuan Li; Chenyi Zhuo; ZuoMing Xu; Chuan Tan; RiHai Ma; JianChu Wang; Jian Pu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 4.  PPARs and Myocardial Infarction.

Authors:  Kay-Dietrich Wagner; Nicole Wagner
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 5.923

5.  Xanthohumol Protects the Rat Myocardium against Ischemia/Reperfusion Injury-Induced Ferroptosis.

Authors:  Jian-Hong Lin; Kun-Ta Yang; Wen-Sen Lee; Pei-Ching Ting; Yu-Po Luo; Ding-Jyun Lin; Yi-Shun Wang; Jui-Chih Chang
Journal:  Oxid Med Cell Longev       Date:  2022-01-17       Impact factor: 6.543

6.  Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy.

Authors:  Giuseppe Di Lorenzo; Luca Scafuri; Ferdinando Costabile; Liuba Pepe; Anna Scognamiglio; Felice Crocetto; Germano Guerra; Carlo Buonerba
Journal:  Future Sci OA       Date:  2022-02-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.